Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time
Authors
Keywords
-
Journal
Nature Communications
Volume 8, Issue -, Pages 14183
Publisher
Springer Nature
Online
2017-01-25
DOI
10.1038/ncomms14183
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model
- (2016) Aleidy Silva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Individualizing liver transplant immunosuppression using a phenotypic personalized medicine platform
- (2016) Ali Zarrinpar et al. Science Translational Medicine
- Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically Driven Platform Technology
- (2015) Hann Wang et al. ACS Nano
- Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
- (2015) Andreas H. Diacon et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Rapid optimization of drug combinations for the optimal angiostatic treatment of cancer
- (2015) Andrea Weiss et al. ANGIOGENESIS
- Evaluation of Moxifloxacin-Containing Regimens in Pathologically Distinct Murine Tuberculosis Models
- (2015) Si-Yang Li et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Pharmacodynamics of Clofazimine in a Mouse Model of Tuberculosis
- (2015) Rosemary V. Swanson et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis
- (2015) Sandeep Tyagi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies
- (2015) Alimuddin Zumla et al. Lancet Respiratory Medicine
- Host-Mediated Bioactivation of Pyrazinamide: Implications for Efficacy, Resistance, and Therapeutic Alternatives
- (2015) Laura E. Via et al. ACS Infectious Diseases
- A streamlined search technology for identification of synergistic drug combinations
- (2015) Andrea Weiss et al. Scientific Reports
- Limited Activity of Clofazimine as a Single Drug in a Mouse Model of Tuberculosis Exhibiting Caseous Necrotic Granulomas
- (2014) Scott M. Irwin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice
- (2013) Jacques H. Grosset et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Advances in the development of new tuberculosis drugs and treatment regimens
- (2013) Alimuddin Zumla et al. NATURE REVIEWS DRUG DISCOVERY
- Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis
- (2012) Kathy Williams et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Use of Fractional Factorial Designs in Antiviral Drug Studies
- (2012) Xianting Ding et al. QUALITY AND RELIABILITY ENGINEERING INTERNATIONAL
- Application of fractional factorial designs to study drug combinations
- (2012) Jessica Jaynes et al. STATISTICS IN MEDICINE
- Clofazimine Analogs with Efficacy against Experimental Tuberculosis and Reduced Potential for Accumulation
- (2011) Yu Lu et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Sterilizing Activity of Novel TMC207- and PA-824-Containing Regimens in a Murine Model of Tuberculosis
- (2011) Rokeya Tasneen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections
- (2011) Zahoor Ahmad et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Systematic quantitative characterization of cellular responses induced by multiple signals
- (2011) Ibrahim Al-Shyoukh et al. BMC Systems Biology
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis
- (2010) Armand Van Deun et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Clinical and Toxicodynamic Evidence that High-Dose Pyrazinamide Is Not More Hepatotoxic than the Low Doses Currently Used
- (2010) J. G. Pasipanodya et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig
- (2010) Z. Ahmad et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Global tuberculosis drug development pipeline: the need and the reality
- (2010) Zhenkun Ma et al. LANCET
- Current development and future prospects in chemotherapy of tuberculosis
- (2010) Eric L. NUERMBERGER et al. RESPIROLOGY
- Addition of PNU-100480 to First-Line Drugs Shortens the Time Needed to Cure Murine Tuberculosis
- (2009) Kathy N. Williams et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis
- (2008) E. Nuermberger et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm
- (2008) Pak Kin Wong et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Using Animal Models to Develop New Treatments for Tuberculosis
- (2008) Eric Nuermberger SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Introduction
- (2008) TUBERCULOSIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started